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Abstract
Background: Total thyroidectomy is increasingly used as a surgical approach for many thyroid conditions.
Subsequently, postoperative hypocalcaemia is observed with increasing frequency, often resulting in prolonged
hospital stay, increased use of resources, reduced quality of life and delayed return to work. The administration of
vitamin D is essential in the therapy of postoperative hypocalcaemia; calcitriol is most commonly used. What has
not been examined so far is whether and how routine preoperative vitamin D prophylaxis using calcitriol can help
to prevent postoperative hypocalcaemia. This study evaluates routine preoperative calcitriol prophylaxis for all
patients who are to undergo a total thyroidectomy, compared with the current standard of post-treatment, i.e.,
selective vitamin D treatment for patients with postoperative hypocalcaemia.
Methods/design: This clinical observational (minimal interventional clinical trial) trial is a multicentre, prospective,
randomized superiority trial with an adaptive design. Datasets will be pseudonymized for analysis. Patients will be
randomly allocated (1:1) to the intervention and the control groups. The only intervention is 0.5 μg calcitriol orally
twice a day for 3 days prior to surgery. For the primary endpoint measure (number of patients with hypocalcaemia),
hypocalcaemia is defined as serum calcium of less than 2.1 mmol/l on any day during the postoperative course;
this measure will be analyzed using a Chi-square test comparing the two groups. Secondary endpoint measures,
such as number of days to discharge, quality of life, and economic parameters will also be analyzed.
Discussion: By virtue of the direct comparison of clinically and economically relevant endpoints, the efficacy as
well as efficiency of preoperative calcitriol prophylaxis of hypocalcaemia will be clarified. These results should be
available 24 months after the first patient has been enrolled. The results will be used to inform a revised practice
parameter guideline of whether or not to recommend preoperative calcitriol for all patients in whom total
thyroidectomy is planned.
Trial registration: Deutsches Register Klinischer Studien, DRKS00005615 (Feb.12.2016).
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Background
Surgery of the thyroid gland is one of the five most com-
mon surgical procedures in Germany, accounting for
some 90000 operations per year [1]. Because subtotal
thyroidectomy is no longer regarded the treatment of
choice for multinodular goitre and Graves’ disease [2],
the number of patients treated by total thyroidectomy
has progressively increased, amounting to 47.9 % in
2011 [3]. This surgical approach aims to prevent recur-
rent disease and is supported by current guidelines, such
as the national S2-guideline issued by the Work Group
of the Scientific Medical Professional Societies [4]. How-
ever, postoperative symptomatic hypocalcaemia due to
transient hypoparathyroidism is a frequent condition
after total thyroidectomy, and is reported to occur in up
to 54 % of patients [5]. Owing to the extent of resection
in the case of total thyroidectomy, the viability of all four
parathyroid glands may be endangered because of surgi-
cal trauma, and their function may be temporarily or
permanently impaired. Risk factors for transient or per-
manent hypoparathyroidism after total thyroidectomy
are higher age, female sex, Graves’ disease, need for
parathyroid autotransplantation, inadvertent excision of
parathyroid glands and low postoperative parathyroid
hormone and serum calcium levels, as well as low pre-
operative serum 25-hydroxy vitamin D level [6].
Postoperative hypocalcaemia affects patients’ physical
health and quality of life and causes a significant eco-
nomic burden for the healthcare system. Acute hypocal-
caemia may cause seizures or cardiac or digestive
dysfunction, as well as phobic psychological disorders.
Hypocalcaemic patients require continuous medical at-
tention, frequent and more extensive biochemical tests
and more medical treatment, including more medica-
tion. Moreover, a recent observational study reported
the average length of hospital treatment of patients with
postoperative hypocalcaemia to be increased by 2.2 days,
compared with that of normocalcaemic patients [5].
Hence, the search for methods to reduce the incidence
and severity of postoperative hypocalcaemia is of clinical,
medical and economic relevance.
Despite ongoing research on the prevention of
postoperative hypocalcaemia, its treatment is well
established and uses oral calcium and vitamin D sup-
plementation. Based on empirical evidence, Tartaglia
et al. [7] were the first to show that routine postopera-
tive administration of calcitriol and calcium salts sig-
nificantly decreased the risk of severe postoperative
hypocalcaemia. Indeed, low levels of vitamin D, as de-
termined by preoperative testing, were shown to be an
independent risk factor for postoperative hypocalcae-
mia [8], suggesting that correction of low vitamin D
levels might be a useful measure to reduce postopera-
tive hypocalcaemia rates.
Vitamin D metabolites and analogues are essential in
the management of postsurgical hypoparathyroidism.
The active form of vitamin D – calcitriol (1,25-dihydrox-
yvitamin D3) – is the preferred clinical option because of
its potency and rapid onset and offset of action. Calci-
triol regulates the expression of TRPV6, which is a cal-
cium entry channel responsible for calcium absorption
in the intestine [9], so that there is a time of onset of ac-
tion of only some 1 or 2 days compared with 10–14 days
for Vitamin D3 (cholecalciferol) [10].
We therefore hypothesized that preoperative adminis-
tration of calcitriol would reduce the rate of hypocalcae-
mia after total thyroidectomy. Moreover, if postsurgical
hypocalcaemia should occur, preoperative vitamin calci-
triol prophylaxis should be helpful in reducing the time
to manage this condition and thus the duration of hos-
pital stay. So far, and to the best of our knowledge, stud-
ies to that effect are still missing.
Aim of the study
The overall aim of this study is to evaluate the effect of
an early onset of calcitriol supplementation on postoper-
ative hypocalcaemia. This study is specifically designed
to evaluate the effects of a preoperative short term ad-
ministration of calcitriol prior to total thyroidectomy
(intervention) in comparison with current standard clin-
ical protocols of postoperative administration of calci-
triol in only those patients who have postoperative
hypocalcaemia (control group). Calcitriol will be admin-
istered according to well-established clinical protocols
and no additional diagnostic interventions are intended,
in order to reduce the likelihood of adverse events. This
study is therefore planned as a post-marketing noninter-
ventional, i.e., observational study. Although we consider
HypoCalViD to be an observational trial rather than a
prospective randomized controlled trial, because patients
are randomly allocated to an interventional and a
noninterventional arm prior to surgery, this trial may
be attributed a ‘minimal-intervention clinical trial’ as
recently defined by EU-directive number 536/2014 of
16 April 2014.
Methods/design
Trial population and eligibility criteria
HypoCalViD is a prospective, randomized, multicentre
study (Fig. 1) involving patients with benign thyroid dis-
ease (Graves’ disease, multinodular goitre, hyperthyroid-
ism) undergoing primary elective total thyroidectomy.
Such patients will be eligible to participate after they
have given their written informed consent. Patients with
conditions that could potentially affect serum calcium
levels, such as musculoskeletal diseases, hyperparathyr-
oidism and medications known to affect calcium metab-
olism are excluded.
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This multicentre study will be conducted in hospital
departments with the required staffing levels and
structural as well as scientific volume qualifications.
Only hospital departments with a special interest in
endocrine surgery and a working volume accounting
for more than 100 total thyroidectomies per year, will
be eligible to participate. The head surgeons of these
departments must be members of the German Association
of Endocrine Surgeons of the Deutsche Gesellschaft für
Allgemein und Viszeralchirurgie.
Sample size
The sample size has been calculated based on assump-
tions generated from a critical appraisal of current evi-
dence. According to prior publications, 25 % of the
patients in the control group can be expected to develop
Fig. 1 Setup of the study
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postsurgical hypocalcaemia as compared with 15 % of
the patients in the intervention group. Assuming an α-
level of 5 % and a power of 80 %, it is calculated that
500 patients must be recruited to obtain significant re-
sults. Assuming a cumulative drop-out rate of 10 %, 700
patients will have to be screened in order to obtain a
total number of 600 patients for random allocation. Sub-
sequently, it is expected that data obtained from 540 pa-
tients will be analyzed at primary endpoint. By using an
adaptive study design, the number of patients will be re-
evaluated after the first 270 patients have been treated,
with complete follow-up.
Feasibility
A small number of high-volume providers will be eli-
gible to participate in this study. As this study will take
place only at high-volume centres chaired by highly
specialized endocrine surgeons, we assume that the op-
eration will be done or supervised by a specialist. Strati-
fication, therefore, is done by centres rather than by
surgeon. In 2013, these high-volume providers took care
of some 2500 surgical cases. All of the potential study
centres are active members of the German Association
of Endocrine Surgeons and have been involved in clinical
multicentre trials in the past. Given these facts, it was
reasonable to assume the average recruitment rate with a
minimum of 60 patients per year and per centre, resulting
in an estimated recruitment phase of 24 months.
Type of trial
This study is designed as a multicentre, parallel-designed,
randomized, clinical, observational trial (minimal-inter-
vention clinical trial).
Randomization
Randomization to the treatment arm and the control
group will be performed in a 1:1 ratio, stratified by each
participating centre. Random allocation of patients will
be dynamical. For the randomization procedure, the
computer program ‘Random Allocation Software’ (Version
1.0.0) will be used; permuted block sizes will be 30 and 60.
Intervention
The specific trial intervention consists of 0.5 μg calcitriol
orally, twice a day for 3 days prior to surgery. The con-
trol therapy consists of any standard conventional hypo-
calcaemia therapy according to current guidelines or
local clinical standards of the participating clinical centre
and adherent to the implemented standards of the re-
spective institution. Standard therapy is defined as the
currently accepted and used treatment for this condition,
based on the results of past research.
Endpoint measures
Primary endpoint measure
The incidence of postsurgical hypoparathyroidism is de-
fined as the primary endpoint measure. Postsurgical
(transient) hypoparathyroidism is defined as the number
of participants with a postoperative serum calcium con-
centration <2.1 mmol/l on any day of the postoperative
hospitalization period. Since there is no evidence- or
consensus-based definition of postoperative hypopara-
thyroidism based on calcium and parathyroid hormone
cutoff levels, we defined postoperative hypoparathyroid-
ism as calcium and parathyroid hormone levels below
the normal range (Ca < 2.1 mmol/l), in line with expert
opinion [11]. Application type, form and dosage of cal-
cium and vitamin D administration therapy to achieve
normocalcaemia will be recorded. Study parameters will
be recorded before surgery, on postoperative days 1 and
2, and at discharge, as well as 30 ± 3 days following
surgery.
Secondary endpoint measures
Secondary endpoint measures comprise the overall dur-
ation of hospital stay, the number of days until restoration
of normal serum calcium level, and hospital resource
utilization, as well as quality of life and reported patient
outcomes.
Duration of hospital stay will be documented accord-
ing to hospital charts. Prior to and one month after sur-
gery, patients will be asked to complete the well-
established SF36 Quality of Life questionnaire [12] and a
questionnaire constructed for the assessment of postop-
erative hypocalcaemia [13]. The number of days needed
to adjust hypocalcaemia to a normal level (calcium level =
2.2 to 2.7 mmol/l) will also be assessed.
Safety endpoint measures
The incidences of serious adverse events, drug-related
adverse events and mortality from any cause (within
30 days of the time of initiation of therapy) are consid-
ered safety endpoint measures of this trial.
Economics-based outcome measures
Direct resource use defined by the number of days of in-
patient hospital treatment will be documented. Direct
medical resource use (direct medical costs) includes the
resource use that is an immediate consequence of the
disease pattern, such as general and specific clinical diag-
nostics, medication (in particular vitamin D analogues
and calcium supplements), secondary interventions and
readmissions. Direct nonmedical resource use is the re-
source use caused by consequences arising from the post-
operative condition, namely the incapacity to work for
those who are otherwise in salaried employment.
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Data analysis
The primary hypothesis is that the rate of postoperative
hypocalcaemia is lower in the preoperative vitamin D
intervention group than in the standard postoperative
treatment control group. The secondary hypothesis
postulates statistically significant clinical and health eco-
nomic benefits through the intervention, as compared
with the current standard treatment.
The primary effectiveness parameter will be analyzed
using a Chi-square test comparing the two groups. Sup-
portive statistical analysis will include logistic regression
with factors in the model to include treatment, study
centre, age, sex and vitamin D status (appropriate base-
line parameters and medical history information may
also be considered). The secondary efficacy parameter
will be compared between the two treatment groups
using a log rank test. In addition, as mentioned, a sup-
portive analysis making use of a Cox proportional haz-
ards regression will also be used, to assess whether there
is a difference between treatment groups while account-
ing for the effect of study centre and other appropriate
baseline and medical history parameters. A planned in-
terim analysis will be performed when 270 study partici-
pants have completed the study.
The interim analysis will re-evaluate the assumptions
made for the study sample size calculation; at this point,
the sample size will be re-estimated unless the trial has
to be stopped as a result of the interim analysis.
Trial organization, registration and ethical aspects
To ensure data integrity and unbiased clinical decisions,
the steering committee will make use of a data manage-
ment plan. This includes regular visits of all trial sites
for source data verification, to ensure continuous moni-
toring of the study data for completeness, validity and
plausibility. During those visits, random samples of par-
ticipants’ files will be monitored to verify accurate data
registration and management.
The trial will be performed according to the Declar-
ation of Helsinki in its current version and Good Clin-
ical Practice guidelines. Before the start of the trial, the
independent ethic committee of the Landesärztekammer
Hessen gave a positive vote on the 16 July 2013: the
committee stated that there were no more ethical and
juridical doubts against the implementation of the trial.
The trial is registered with the Deutsches Register
Klinischer Studien [14], number DRKS00005615.
Discussion
Total thyroidectomy is currently the standard surgical
procedure for various conditions of the thyroid gland;
the aim is to reduce the incidence of recurrent disease
and thus avoid re-operations. As a consequence of
the more extensive surgical procedure, postoperative
hypoparathyroidism is affecting an increasing number
of patients. In addition, it has become a burden for
the health system, because hypocalcaemic patients re-
quire longer in-patient treatment and more medical
resources. HypoCalViD has the potential to prove the
clinical usefulness of a rather simple intervention with
a well-established protocol, commonly used for the
correction of postsurgical hypocalcaemia: calcitriol.
A potential weakness of the protocol is that there is
neither the patient nor the investigator is blinded. How-
ever, as the primary endpoint (serum calcium concentra-
tion) is measured using standardized methods and
independently of the respective intervention, a placebo
effect is unlikely to occur. Secondary endpoint measures,
such as the score on the SF36 questionnaire addressing
the participants’ quality of life, might also be influenced
by the patients’ awareness of having been part of the
intervention or control group.
Because this trial aims to address the most common
thyroid procedure, i.e., thyroidectomy for benign thyroid
conditions, comprising more than 80 % of thyroid proce-
dures, nonbenign reasons for total thyroidectomy were
excluded. Patients with malignant conditions often re-
quire more extensive resections and might experience
hypocalcaemia more often. There might be an even
greater effect of calcitriol in these cases. However, these
cases only make up for some 5–10 % of all thyroid
procedures and the extent of surgery is tailored to the
individual patient, making it difficult to study such a
heterogenous group.
To obtain a comparable group of postsurgical patients
with the same extent of surgical trauma and because a
large number of patients is needed to be able to demon-
strate a significant effect of the intervention, we decided
to exclude malignant deceases for the specific purpose
of this study.
Calcitriol will be given to the patients regardless of
their vitamin D status, although prior evidence suggests
that including patients only with a documented low vita-
min D level would potentially increase the likelihood of
a positive effect of calcitriol administration (the inter-
vention) on both the primary and secondary outcome
parameters. The main reason for not taking preoperative
vitamin D levels into account is that this study aims at
not interfering with the current standard of care or
established guideline-oriented clinical management of
patients with postoperative hypocalcaemia after thyroid
surgery.
Although the assessment of vitamin D levels is recom-
mended by guidelines addressing common problems of
older people, such as osteoporosis, routine assessment of
vitamin D is not yet established in clinical practice in
Germany. In addition, determination of a patient’s
vitamin D level incurs a minimum charge of €27.98 – with
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a potential for additional costs of €2.60 for taking the
blood sample – while the calcitriol prophylaxis employed
in this study proposal incurs an additional cost of less than
€5 per patient. Because such a routine prophylaxis is
considerably less costly and – given a positive outcome of
this study – much easier to implement, the trial is likely to
offer a realistic chance of optimizing treatment of patients
undergoing thyroid surgery.
The primary endpoint measure is defined by total
serum calcium level. Although ionized calcium level
might be more specific in detecting hypocalcaemia, espe-
cially in the presence of malnutrition, ionized calcium is
not a commonly used laboratory parameter during post-
surgical follow-up of thyroid patients. We decided to ask
for total calcium level only, as most hospitals and surgi-
cal departments make use of this parameter. Moreover,
the observational nature of this trial intends not to inter-
fere with the respective standard of treatment. There-
fore, no additional parameters other than the individual
trial sites’ ‘usual’ parameters were included.
Moreover, the majority of patients with elective benign
thyroid surgery should not suffer from severe protein
deficiency.
By virtue of the direct comparison of clinically and
economically relevant endpoints, this trial should assist
in clarifying the efficacy as well as efficiency of preoperative
calcitriol prophylaxis for patients undergoing total thyroid-
ectomy. First results should be available 24 months after
the first patient has been enrolled. The results will be used
as a rationale to propose a revised practice parameter
guideline to the CAEK-DGAV (Chirurgische Arbeitsge-
meinschaft Endokrinologie, Deutsche Gesellschaft für All-
gemein- und Viszeralchirurgie) of the German Association
of Surgeons, whether or not to recommend general pre-
operative calcitriol supplementation for patients in whom a
total thyroidectomy is planned.
Trial status
Up to now, six centres are initiated and are actively recruit-
ing patients. The first patient was enrolled on 4 July 2014.
The expected recruitment period will last until July 2016.
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CAEK-DGAV: Chirurgische Arbeitsgemeinschaft Endokrinologie, Deutsche
Gesellschaft für Allgemein- und Viszeralchirurgie.
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